Keywords
Lung Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

273 Search results.

Treatment Summary NSCLC Stage III RTOG NCT00533949

- 2/6/19 - 1 form, 3 itemgroups, 36 items, 1 language
Itemgroups: RTOG clinical trial administrative data, Assessment of Chemotherapy, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
NCT00533949 TF: Radiation Therapy Oncology Group Phase III High-dose Vs Standard-dose Conformal XRT with Chemotherapy Treatment Summary Form High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24FB4F78-9A8F-669C-E044-0003BA3F9857

Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC Follow-up Form - 2556229v1.0 - RTOG-0617 F1: Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC Follow-up Form

- 2/5/19 - 1 form, 4 itemgroups, 45 items, 1 language
Itemgroups: MODULE 1, MODULE 2, Has patient been diagnosed with a new progression?, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
RTOG-0617 F1: Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC Follow-up Form High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24F6F134-391D-15F5-E044-0003BA3F9857

Eligibility Lung Cancer NCT01386697

- 1/17/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
DIBH Proton Planning; ODM derived from: https://clinicaltrials.gov/show/NCT01386697

Eligibility Lung Cancer NCT02428049

- 1/4/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02428049

Eligibility Lung Neoplasms NCT01130753

- 5/27/18 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01130753

Eligibility Lung Neoplasms NCT00768131

- 5/27/18 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel; ODM derived from: https://clinicaltrials.gov/show/NCT00768131

Eligibility Lung Neoplasms NCT00657423

- 5/27/18 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00657423

Eligibility Lung Cancer NCT01657617

- 5/26/18 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01657617

Eligibility Lung Cancer NCT01281787

- 5/26/18 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01281787

Eligibility Lung Cancer NCT01261598

- 5/26/18 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival; ODM derived from: https://clinicaltrials.gov/show/NCT01261598

Eligibility Lung Cancer NCT00989690

- 5/26/18 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Criteria
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00989690

Eligibility Lung Cancer NCT00986297

- 5/26/18 - 1 form, 1 itemgroup, 18 items, 1 language
Itemgroup: Criteria
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status; ODM derived from: https://clinicaltrials.gov/show/NCT00986297